ストックスクリーナーアプリを入手
8.35
3.47%
-0.30
アフターアワーズ：
8.37
0.02
+0.24%
Cybin Inc (CYBN) 最新ニュース
Cybin Provides Corporate Update and Highlights Positive Regulato - GuruFocus
Cybin Advances Phase 3 Program Amid Positive Regulatory Signals - TipRanks
# Cybin begins phase 3 trials for depression treatment CYB003 - Investing.com Australia
Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics - marketscreener.com
# Cybin begins phase 3 trials for depression treatment CYB003 By Investing.com - Investing.com India
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics | CYBN Stock News - GuruFocus
Should You Buy Polkadot While It's Under $5? - The Globe and Mail
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - The Globe and Mail
Prediction: This Company Will Be the Most Valuable AI Stock in 2026 - The Globe and Mail
Billionaire Bill Ackman Just Scooped Up Shares of This Unstoppable Stock - The Globe and Mail
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Per - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference | CYBN Stock News - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference - Business Wire
Cybin to Participate in the 2025 Psychedelic Science Conference - GuruFocus
Cybin to Participate in the 2025 Psychedelic Science Conference | CYBN Stock News - GuruFocus
Crypto's hottest new trend: publicly traded companies buying bunches of bitcoin - The Globe and Mail
(CYBN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Cybin, Inc: The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN St - GuruFocus
Market Analysis: June 6th, 2025 - The Globe and Mail
lucid capital markets initiates buy rating on cybin stock - Investing.com Australia
lucid capital markets initiates buy rating on cybin stock By Investing.com - Investing.com South Africa
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN Stock News - GuruFocus
Cybin secures U.S. patent for program targeting generalized Anxiety disorder and depression - Proactive Investors
Cybin, Inc.The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Why MongoDB Stock Popped Today - The Globe and Mail
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder - BioSpace
Cybin secures patent for anxiety disorder treatment CYB004 - Investing.com
Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments - marketscreener.com
Cybin secures patent for anxiety disorder treatment CYB004 By Investing.com - Investing.com Canada
Cybin Secures U.S. Patent for CYB004 Program in Anxiety Disorder Treatment - TipRanks
Cybin (CYBN) Secures U.S. Patent for CYB004 Program | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting its CYB004 Pro - GuruFocus
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Transcript : Cybin Inc.Special Call - marketscreener.com
(CYBN) Proactive Strategies - news.stocktradersdaily.com
Prediction: Dogecoin Will Plummet to New Lows by the End of the Year. Here's Why. - The Globe and Mail
Cboe Canada Single Security - Cboe Global Markets
Billionaire CEO Jamie Dimon Just Delivered a Stark Warning to the Market. Here Are 3 Things Investors Should Do. - The Globe and Mail
This Chinese Robotaxi Stock Could Be an Even Better Buy Than Tesla Before June - The Globe and Mail
Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat - TipRanks
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - BioSpace
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 | CYBN Stock News - GuruFocus
Cybin CEO Reveals Latest on Phase 3 Psychedelics Program and FDA Developments in Exclusive Analyst Chat - Stock Titan
Cybin Engages Thermo Fisher Scientific To Provide U.S.-Based Manufacturing for Its CYB003 Program - Technology Networks
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Acce - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics | CYBN Stock News - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Yahoo Finance
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):